Acute myeloid leukemia (AML) is the most common acute leukemia in the United States, comprising 33 percent of all leukemias. The cancer progresses rapidly if not treated, making timely diagnosis an important goal. Recent diagnostic tests and treatment options such as stem cell transplantation are improving the remission and cure rates for some patients with AML, but generally, the standard of care for AML has not changed in 40 years.
Read below to learn more about the diagnosis, treatment, and prognosis of AML, and how clinical trials are helping researchers develop new therapies for this disease.
This “Patient Education” tear sheet was produced in collaboration with The Leukemia & Lymphoma Society (lls.org).
Patient Education: What Is Acute Myeloid Leukemia?